Daratumumab Not Cost-Effective for Multiple Myeloma
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Home
Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
Abecma Approved for Relapsed/Refractory Multiple Myeloma
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
Can Premedications, Infusion Rates Be Adjusted Safely With Daratumumab for Multiple Myeloma?
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis
Researchers sought to determine whether rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality.
SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
BTK Inhibitors for CLL Lower Response to Some Vaccines
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Evaluating the Role of Platelets in Ischemia-Reperfusion Injury Post-Stroke
Researchers are examining the role of platelets as drivers of inflammation, which may provide a mechanistic link with ischemia-reperfusion injury.
Pre-Transplantation MRD Status Predicts Survival in Acute Leukemia
Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
